These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31257722)

  • 61. Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects.
    Zhang P; Xiao Y; Sun X; Lin X; Koo S; Yaremenko AV; Qin D; Kong N; Farokhzad OC; Tao W
    Med; 2023 Mar; 4(3):147-167. PubMed ID: 36549297
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Organoids technology for advancing the clinical translation of cancer nanomedicine.
    Zhao DK; Liang J; Huang XY; Shen S; Wang J
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1892. PubMed ID: 37088100
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Anticancer Nanotherapeutics in Clinical Trials: The Work behind Clinical Translation of Nanomedicine.
    Parodi A; Kolesova EP; Voronina MV; Frolova AS; Kostyushev D; Trushina DB; Akasov R; Pallaeva T; Zamyatnin AA
    Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362156
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Application of nanotechnology in biomedicine.
    Navalakhe RM; Nandedkar TD
    Indian J Exp Biol; 2007 Feb; 45(2):160-5. PubMed ID: 17375555
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tailored Approaches in Drug Development and Diagnostics: From Molecular Design to Biological Model Systems.
    Sahlgren C; Meinander A; Zhang H; Cheng F; Preis M; Xu C; Salminen TA; Toivola D; Abankwa D; Rosling A; Karaman DŞ; Salo-Ahen OMH; Österbacka R; Eriksson JE; Willför S; Petre I; Peltonen J; Leino R; Johnson M; Rosenholm J; Sandler N
    Adv Healthc Mater; 2017 Nov; 6(21):. PubMed ID: 28892296
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The National Cancer Institute Investment in Biomechanics in Oncology Research.
    Dickherber A; Hughes SK; Zahir N
    Adv Exp Med Biol; 2018; 1092():1-10. PubMed ID: 30368745
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 69. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide.
    Minig L; Trimble EL; Birrer MJ; Kim KY; Takebe N; Abrams JS
    Gynecol Oncol; 2010 Feb; 116(2):177-80. PubMed ID: 19889449
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cancer nanomedicine: from drug delivery to imaging.
    Chow EK; Ho D
    Sci Transl Med; 2013 Dec; 5(216):216rv4. PubMed ID: 24353161
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Translational nanomedicine: status assessment and opportunities.
    Murday JS; Siegel RW; Stein J; Wright JF
    Nanomedicine; 2009 Sep; 5(3):251-73. PubMed ID: 19540359
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Overcoming obstacles in the tumor microenvironment: Recent advancements in nanoparticle delivery for cancer theranostics.
    Overchuk M; Zheng G
    Biomaterials; 2018 Feb; 156():217-237. PubMed ID: 29207323
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Carolina Center of Cancer Nanotechnology Excellence: past accomplishments and future perspectives.
    Juliano RL; Sunnarborg S; DeSimone J; Haroon Z
    Nanomedicine (Lond); 2011 Jan; 6(1):19-24. PubMed ID: 21182415
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Trends in Nanotechnology for in vivo Cancer Diagnosis: Products and Patents.
    do Nascimento T; Tavares M; Monteiro MSSB; Santos-Oliveira R; Todeschini AR; de Souza VT; Ricci-Júnior E
    Curr Pharm Des; 2020; 26(18):2167-2181. PubMed ID: 32072890
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Detecting and destroying cancer cells in more than one way with noble metals and different confinement properties on the nanoscale.
    Dreaden EC; El-Sayed MA
    Acc Chem Res; 2012 Nov; 45(11):1854-65. PubMed ID: 22546051
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Insights From Building a New National Cancer Institute Community Oncology Research Program Site.
    Saphner T; Thompson MA; Planton S; Singh M; Glandt N; Robinson L; DeBartolo J
    WMJ; 2016 Aug; 115(4):191-5. PubMed ID: 29099156
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nanotechnology translation in vascular diseases: From design to the bench.
    Zhou Y; Yue T; Ding Y; Tan H; Weng J; Luo S; Zheng X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1919. PubMed ID: 37548140
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Bibliometric analysis of nanotechnology applied in oncology from 2002 to 2011.
    Dong X; Qiu XC; Liu Q; Jia J
    Tumour Biol; 2013 Dec; 34(6):3273-8. PubMed ID: 23959469
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Nano-phototherapy: Favorable prospects for cancer treatment.
    Merlin JPJ; Crous A; Abrahamse H
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1930. PubMed ID: 37752098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.